Boehringer Ingelheim begins trials for ‘Viagra for women’

Share this article:
Boehringer Ingelheim has begun trials on a sex drug that has been dubbed a “Viagra for women,” because it works directly on the pleasure zones of the female brain to restore low libido. The drug, known as flibanserin, was originally tested as an anti-depressant. Participants in those trials reported that while their depression was no better, they had experienced a boost in sexual desire. Boehringer is reportedly conducting four trials on 5,000 women in 220 locations and is hoping to receive approval from the FDA in 2009. Boehringer’s medical director for the UK, Dr. Charles de Wet, told the British newspaper The Times that “no excessive sexual side effects have been reported from the treatment in any clinical trial.” Flibanserin takes several weeks for a significant effect to build up in the brain, meaning that, unlike Viagra, it cannot be “popped” in advance of an evening out.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.